Serological and Molecular Testing in Viral Hepatitis: An Update

Weston, Shiobhan R.; Martin, Paul

doi:10.1155/2001/390294

Cited by 14 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For HBV, NATs, and HBsAg detection play different roles in the diagnosis or management of chronic hepatitis . Additionally, for the diagnosis of HAV infection, the detection of anti‐HAV IgM is still the gold standard and HAV RNA testing is used as a research tool . For these reasons, serological approaches including anti‐HAV IgM, HBsAg, and anti‐HCV IgG are still important for viral hepatitis detection in clinical settings.…”

Section: Discussionmentioning

confidence: 99%

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Kweon

Lim

Kim

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Background Although immunoassays play a major role in the detection of hepatitis viruses, there is a need for a point‐of‐care (POC) test. We evaluated the EuDx‐HE (A,B,C) kit (EUDIPIA, Cheongju, Korea), which detects anti‐hepatitis A virus (HAV) immunoglobulin M (IgM), hepatitis B virus surface antigen (HBsAg), and anti‐hepatitis C virus (HCV) immunoglobulin G (IgG) simultaneously using an immunochromatographic method within 15 minutes. Methods A total of 1581 serum samples including 57, 477, and 451 samples positive for anti‐HAV IgM, HBsAg, and anti‐HBV IgG, respectively, were analyzed. We investigated the diagnostic accuracy of the EuDx‐HE (A,B,C) kit by comparison with SD BIOLINE POC kits (Abbott, Chicago, IL) using Architect immunoassays as a reference method. Results For anti‐HAV IgM and HBsAg detection, the EuDx‐HE (A,B,C) kit showed a higher sensitivity and a slightly lower specificity than the SD BIOLINE kit. For anti‐HCV IgG detection, the EuDx‐HE (A,B,C) kit had a higher sensitivity and a higher specificity than the SD BIOLINE kit. The agreement for positivity between the POC tests was >89.47%, with κ values of 0.844, 0.941, and 0.943 for HAV, HBV, and HCV, respectively. Conclusion The EuDx‐HE (A,B,C) kit showed an acceptable clinical performance for detecting anti‐HAV IgM, HBsAg, and anti‐HCV.

show abstract

Section: Discussionmentioning

confidence: 99%

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Kweon

Lim

Kim

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…1). 10 Samples for HCV-RNA testing in dialysis patients should be obtained prior to the HD procedure; heparin used during dialysis sessions can interfere with the PCR technique. In addition, the HD procedure lowers HCV-RNA levels by adsorption of HCV RNA onto the inner surface of dialyzers and destruction of viral particles by the hydraulic pressure exerted by the bood for dialysis.…”

Section: Epidemiology and Diagnosis Of Hcv Infection In Esrdmentioning

confidence: 99%

Hepatitis C infection and the patient with end-stage renal disease

2002

Self Cite

View full text Add to dashboard Cite

Hepatitis C virus (HCV) remains common in patients with end-stage renal disease (ESRD)and is an important cause of liver disease in this population. Acquisition of HCV infection continues to occur in dialysis patients because of nosocomial spread. The natural history of HCV in dialysis patients remains controversial because the course of HCV typically extends over decades, whereas dialysis patients have higher morbidity and mortality rates than those of the general population limiting long-term follow-up. However, recent reports suggest that HCV infection affects the survival of chronic dialysis patients as well as renal transplant ( L iver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) treated by dialysis or transplantation. 1 Viral hepatitis was suspected to be prevalent in patients with ESRD maintained on chronic hemodialysis (HD) nearly 3 decades ago. Development of diagnostic testing for hepatitis B virus (HBV) confirmed a high incidence and prevalence of HBV infection both in patients and staff in HD units. A number of measures mandated by the Centers for Disease Control, including isolation of hepatitis B surface antigen-positive patients, dedicated dialysis machines, and regular surveillance for HBV infection, dramatically reduced the spread of HBV in this setting by the late 1970s. However, many cases of liver disease in ESRD were unexplained and were ascribed to non-A, non-B hepatitis. Once the hepatitis C virus (HCV) was cloned, 2 it rapidly became evident that HCV was frequent in patients with ESRD on HD and that HCV transmission was occurring within HD units in the absence of the usual parenteral risk factors (i.e., blood transfusion or illicit drug use) ( Table 1). A number of other important facets of HCV infection in ESRD patients have been recognized, including false-negative serologic tests and an absence of biochemical dysfunction despite viremia. However, despite this, progressive liver disease can occur and is a particular concern in the patient who is a renal transplantation (RT) recipient. Epidemiology and Diagnosis of HCV Infection in ESRDWith first-and second-generation serologic testing for HCV available, a number of investigators 3 reported a high prevalence of anti-HCV seropositivity in patients with ESRD on chronic dialysis, most of whom were also viremic by polymerase chain reaction (PCR). A high rate of false-negative serologic testing was also noted. Bukh et al. 4 reported that 2.6% of dialysis patients seronegative by second-generation enzyme-linked immunosorbent assay (ELISA) were viremic by PCR. However, the more recent

show abstract

“…Bunların yanı sıra diyaliz sırasında rutin olarak kullanılan heparin PZR ile etkileşmekte ve yalancı negatif sonuçlara neden olabilmektedir. Bu nedenle PZR çalışılacak kan örneğinin diyaliz öncesinde alınması önerilmektedir (27). Ça-lışmamızda kullanılan tüm kan örnekleri hastaya diyaliz uygulanmadan hemen önce alınmıştır.…”

Section: İrdelemeunclassified

Frequency and Epidemiologic Characteristics of Hepatitis C Virus Infection in Patients Receiving Hemodialysis in Our Region

Bozkurt¹,

Aygen²,

Yıldız³

et al. 2012

Klimik Dergisi

View full text Add to dashboard Cite

ÖzetAmaç: Hepatit C virusu (HCV) hemodiyalize giren hasta popülas-yonunda sık görülen bir infeksiyon etkenidir. Çalışmada bölge-mizdeki hemodiyaliz hastalarında HCV infeksiyonunun sıklığının ve epidemiyolojik özelliklerinin araştırılması amaçlanmıştır. Yöntemler: Çalışmaya rutin olarak hemodiyalize giren 16 yaşın üzerindeki kronik böbrek yetmezliği olan 100 hasta alındı. Hastaların demografik verileri, HCV için olası bulaşma yolları, hemodiyalize giriş yolu, hemodiyaliz süresi, karaciğer fonksiyon testleri, hepatit göstergeleri ve HCV RNA sonuçları araştırıldı. Hepatit göstergeleri "enzyme immunoassay" (EIA, Abbott Architect, Almanya) ile test edildi. Plazmada HCV RNA "real time" polimeraz zincir reaksiyonu (PZR, COBAS TaqMan Roche, Almanya) ile araştırıldı. PZR testinin ölçüm aralığı 25-3.91x10 8 İÜ/ ml, duyarlılığı ise 25 İÜ/ml idi. Bulgular: Hastaların yaş ortalaması 58.6±13.9 yıldı ve %56'sı erkekti. Ortalama diyaliz süresi 4.8±3.9 (1-19) yıl bulundu. Alanin aminotransferaz ve aspartat aminotransferaz değerleri ortalaması sırasıyla 17±1.1 İÜ/lt ve 16.1±7.2 İÜ/lt idi. En sık bulaşma yolu cerrahi girişim, ikinci sıklıkla kan transfüzyonu olarak saptandı. Çalışmaya dahil edilen 100 hastanın 16'sında anti-HCV ve HCV RNA testlerinden en az biri pozitifti. Hastalardan 10'unda anti-HCV pozitifliği, 11'inde HCV RNA pozitifliği belirlendi. Anti-HCV'si pozitif olan 10 hastadan 5'inin HCV RNA'sı pozitif bulundu. Anti-HCV'si negatif olan 90 hastanın 6 (%6.7)'sında HCV RNA pozitifti. Bu hastaların HCV RNA değerleri 75-338 İÜ/lt arasındaydı. AbstractObjective: Hepatitis C virus (HCV) is a common cause of infection in patients receiving hemodialysis. In this study, we aimed to determine frequency and epidemiological characteristics of HCV infection in hemodialysis patients. Methods: One hundred patients with end-stage renal disease, over 16 years old, receiving hemodialysis were enrolled in this study. Demographic data, possible routes of transmission, type of vascular access, duration of hemodialysis, liver function tests, markers of hepatitis and HCV RNA were all evaluated. Serological markers were tested with enzyme immunoassay (EIA, Abbott Architect, Germany). HCV RNA was studied by using real-time polymerase chain reaction (PCR, COBAS TaqMan Roche, Germany). Measurement range of the PCR test was 25-3.91x10 8 IU/mL and the sensitivity of the test was 25 IU/mL. Results: The mean age of the patients was 58.5±13.9 years and 56% were male. The average duration of dialysis was 4.8±3.9 (1-19) years. The mean levels of aspartate aminotransferase and alanine aminotransferase were 17±1.1 IU/L and 16.1±7.2 IU/L, respectively. Surgical procedures and blood transfusion were the most common route of transmission. Of the 100 patients, 16 were positive for at least one of anti-HCV and HCV RNA. 10 out of 100 patients were positive for anti-HCV and 11 were positive for plasma HCV RNA. Five of the 10 patients whose anti-HCV results were positive were also found to be positive for HCV RNA. Six (6.7%) out of 90 anti-HCV-negative patien...

show abstract

Serological and Molecular Testing in Viral Hepatitis: An Update

Cited by 14 publications

References 62 publications

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Hepatitis C infection and the patient with end-stage renal disease

Frequency and Epidemiologic Characteristics of Hepatitis C Virus Infection in Patients Receiving Hemodialysis in Our Region

Contact Info

Product

Resources

About